The US House of Representatives Committee on Oversight & Accountability committee has approved the Biosecure Act, which will require American companies to cease working with WuXi AppTec, among other Chinese biotechs, by 2032. This follows a vote on an earlier draft by the Senate’s Homeland Security & Governmental Affairs committee. The Act must now go through votes in both chambers and be signed into law by the President.
CDMO Sterling Pharma Solutions has announced a $3 million investment in antibody-drug conjugate (ADC) development and manufacturing at its facility at Germantown, Wisconsin. It has commissioned a dedicated GMP suite, which will incorporate a modular isolator with containment capabilities down to less than 1 ng/m3.
CEFIC sector group the European Fine Chemicals Group (EFCG), which represents some 350 API and fine chemical sites in Europe, has joined the Critical Medicines Alliance. This is a European Commission initiative that seeks to bring stakeholders together to share challenges and determine the most suitable actions to rebuild resilience in European medicine supply chains
Lonza has launched its AI-enabled route scouting service offering for small molecules, which combines AI-enabled computer-aided synthesis planning technology from Elsevier operation Reaxys with its own process R&D expertise and supply chain databases. This aims to streamline synthetic route identification.
Blue Wolf Capital Partners, a US-based private equity firm, has agreed to acquire seven Recipharm sites from EQT Private Equity, subject to regulatory approval in a deal that should close in Q4. These are located at Solna, Strängnäs, Höganäs, Karlskoga and Uppsala in Sweden; Pessac, France; and Parets, Spain.
Jubilant Ingrevia has commissioned a new 2,000 tonnes/year facility for diketene derivatives at Gajraula in India’s Uttar Pradesh state. The company’s supplies these to the pharmaceuticals, agrochemicals and other industries, including the US and the EU. This and early efforts to get customer product approvals, are expected to account for much of the capacity utilisation in the coming months.
EuroAPI has suspended all API production at its site in Brindisi, Italy, until further notice. This followed an internal audit in which “quality control deficiencies due to potential local misconduct” were identified. These are being further investigated.
